Nonalcoholic Steatohepatitis Treatment Market Growth Factors 2018 – 2026

Nonalcoholic steatohepatitis treatment (NASH) is a syndrome which causes liver damage in non-alcoholic patients. It develops most often in patients with at least one factors such as dyslipidemia, obesity, and glucose intolerance. NASH pathogenesis is not clearly understood however is considered to be linked with insulin resistance. It is diagnosed with the help of blood tests, imaging tests, and sometimes liver biopsy. Treatment of the NASH includes elimination of causes and risk factors such as reducing fat level in the body. NASH is also considered to be one of the chief causes of cirrhosis which can lead to complete liver failure.


Market Dynamics

Obesity, high blood pressure and cholesterol level, type 2 diabetes and metabolic syndrome are the major cause of the NASH onset. Increasing prevalence of these conditions worldwide is expected to drive the global nonalcoholic steatohepatitis treatment market growth during the forecast period. According to the International Diabetes Federation 2017 data, approximately 425 million people were suffering from diabetes in the world and 82 million cases were in the South East Asia region which is expected to reach 151 million by 2045.

However, diagnosis of the NASH can be difficult to catch in an early stage and can take years before patients show any sort of symptoms which is a major factor hampering the nonalcoholic steatohepatitis treatment market.

Nonalcoholic steatohepatitis (NASH) is a form of nonalcoholic fatty liver disease (NAFLD) in which a person have hepatitis and inflammation of the liver, and can cause liver damage. NASH can lead to complications, such as cirrhosis and liver cancer. Patients with NASH have high chance of mortality due to liver-related causes such as liver failure.

Lifestyle modification, including change in diet and exercise, is the basic therapy recommended for nonalcoholic fatty liver disease. However, in some cases lifestyle modification is difficult to achieve and to sustain, and therefore required other treatments including medicine.

Currently available drugs for the treatment of NAFLD were historically been given for other indications. For instance, Orlistat, a gut lipase inhibitor, is indicated for decrease in the dietary fats absorption. According to the National Center for Biotechnology Information (NCBI) 2017 study, Orlistat has been approved for treatment of obesity and is available over the counter in the U.S. for weight loss. Orlistat-mediated weight loss is related with reduction in hepatic steatosis.

The global nonalcoholic steatohepatitis treatment market size was valued at US$ 1,119.9 million in 2017 (based on existing approved therapies anti-diabetics, vitamins, dietary supplements, and others) and is expected to witness a CAGR of 42.7% over the forecast period (2018 – 2026).

Nonalcoholic Steatohepatitis Treatment Market – Regional Insights

On the basis of region, the global nonalcoholic steatohepatitis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America and Europe nonalcoholic steatohepatitis treatment market is expected to foresee significant growth owing to increasing incidence of obesity and fatty liver.

According to the National Health and Nutrition Examination Survey, the proportion of NAFLD among chronic liver diseases increased from 47% to 75% between 1988 and 2008 in the U.S. According to the National Institutes of Health, in 2015 nearly 3 to 12% of adults in the U.S. were suffering from NASH. The major reason for this increase was an increase in metabolic risk factors. According to the Journal of Hepatology, in 2013, approximately one-third of adults exhibit a pattern of NAFLD in Europe.

Nonalcoholic Steatohepatitis Treatment Market – Competitive Landscape

Key players operating in the global nonalcoholic steatohepatitis treatment market include AstraZeneca Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc.


Detailed Segmentation:

  • Global Nonalcoholic Steatohepatitis Treatment Market, By Drug:
    • Cenicriviroc
    • Elafibranor
    • Ocaliva (Obeticholic Acid)
    • Selonsertib
  • Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy